These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 19359261)

  • 1. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.
    Greenberg JD; Reed G; Kremer JM; Tindall E; Kavanaugh A; Zheng C; Bishai W; Hochberg MC;
    Ann Rheum Dis; 2010 Feb; 69(2):380-6. PubMed ID: 19359261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of rheumatoid arthritis treatments and the risk of serious infections.
    Grijalva CG; Kaltenbach L; Arbogast PG; Mitchel EF; Griffin MR
    Rheumatology (Oxford); 2010 Jan; 49(1):82-90. PubMed ID: 19906833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
    Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
    Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
    Greenberg JD; Kremer JM; Curtis JR; Hochberg MC; Reed G; Tsao P; Farkouh ME; Nasir A; Setoguchi S; Solomon DH;
    Ann Rheum Dis; 2011 Apr; 70(4):576-82. PubMed ID: 21109516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
    Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
    Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
    Strangfeld A; Eveslage M; Schneider M; Bergerhausen HJ; Klopsch T; Zink A; Listing J
    Ann Rheum Dis; 2011 Nov; 70(11):1914-20. PubMed ID: 21791449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
    Baddley JW; Winthrop KL; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    Ann Rheum Dis; 2014 Nov; 73(11):1942-8. PubMed ID: 23852763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
    Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Symmons DP;
    Ann Rheum Dis; 2011 Oct; 70(10):1810-4. PubMed ID: 21784730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.
    Ma MH; Kingsley GH; Scott DL
    Rheumatology (Oxford); 2010 Jan; 49(1):91-8. PubMed ID: 19917618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
    Kang EH; Jin Y; Tong AY; Desai RJ; Kim SC
    Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1383-1391. PubMed ID: 31376333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.
    Cobo-Ibáñez T; Descalzo MÁ; Loza-Santamaría E; Carmona L; Muñoz-Fernández S
    Rheumatol Int; 2014 Jul; 34(7):953-61. PubMed ID: 24414744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.
    Mor A; Bingham CO; Kishimoto M; Izmirly PM; Greenberg JD; Reddy S; Rosenthal PB
    Ann Rheum Dis; 2008 Apr; 67(4):462-5. PubMed ID: 17711866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.
    Au K; Reed G; Curtis JR; Kremer JM; Greenberg JD; Strand V; Furst DE;
    Ann Rheum Dis; 2011 May; 70(5):785-91. PubMed ID: 21288960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
    Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.